ライフサイエンスコーパス: withdrawal syndrome

1 0% by minimal, moderate, and severe alcohol withdrawal syndrome).

2 especially for people who have experienced a withdrawal syndrome.

3 AR) agonists that may result in antiandrogen withdrawal syndrome.

4 ctivity 24 h later, suggestive of a caffeine withdrawal syndrome.

5 ons, and are therefore at increased risk for withdrawal syndrome.

6 trexone, substance dependence, and substance withdrawal syndrome.

7 ic opiates has been implicated in the opiate withdrawal syndrome.

8 , which contributes to genesis of the opioid withdrawal syndrome.

9 l and autonomic manifestations of the opiate withdrawal syndrome.

10 havioral features associated with the opiate withdrawal syndrome.

11 ealthcare system risk factors for iatrogenic withdrawal syndrome.

12 CC glutamate is associated with the cannabis withdrawal syndrome.

13 osure, and increased frequency of iatrogenic withdrawal syndrome.

14 rrupting PD treatment might lead to a severe withdrawal syndrome.

15 e with more severe manifestations of alcohol withdrawal syndrome.

16 ns, which constitute a severe symptom of the withdrawal syndrome.

17 c effect of FKBP5 on the severity of alcohol withdrawal syndrome.

18 drawal symptoms in ICU patients with alcohol withdrawal syndrome.

19 ail during the first 2 weeks of the nicotine withdrawal syndrome.

20 ccounts for some but not all aspects of this withdrawal syndrome.

21 ich are likely to contribute to beta-blocker withdrawal syndrome.

22 amide and is likely involved in bicalutamide withdrawal syndrome.

23 ng the validity and significance of cannabis withdrawal syndrome.

24 l will lead to a better understanding of the withdrawal syndrome.

25 antigen, which might result in antiandrogen withdrawal syndrome.

26 ted by a less severe antagonist-precipitated withdrawal syndrome.

27 ible pathway that might contribute to the HF withdrawal syndrome.

28 ibed to treat depression are associated with withdrawal syndromes.

29 on, and treatment of neonatal and iatrogenic withdrawal syndromes.

30 fe-threatening complications, dependence and withdrawal syndromes.

31 s appear similar to those of other substance withdrawal syndromes.

32 ubation stridor, 22% vs. 53% (p < .001); and withdrawal syndromes, 0% vs. 43% (p < .001).

33 Subjects with iatrogenic withdrawal syndrome (544/1,157; 47%) were younger and mo

34 Chronic opioid-induced drug dependence and withdrawal syndrome after opioid cessation remain a seve

35 ng as criteria, adding cannabis and caffeine withdrawal syndromes, aligning tobacco use disorder crit

36 before weaning to better prevent iatrogenic withdrawal syndrome among at-risk patients.

37 2 test cases: 1) opioids and neonatal opioid withdrawal syndrome and 2) valproate and congenital malf

38 ission has long been implicated in the acute withdrawal syndrome and as a key signal for dependence-r

39 rrence, predictors, and prognosis of alcohol withdrawal syndrome and delirium tremens in patients wit

40 Measures included occurrence of alcohol withdrawal syndrome and delirium tremens, injury charact

41 ity, validity, and time course of a cannabis withdrawal syndrome and have begun to explore the effect

42 Attempts at abstinence lead to alcohol withdrawal syndrome and hyperalgesia, increasing the ris

43 al glutamate is associated with the cannabis withdrawal syndrome and recently examined possible assoc

44 Serious adverse events included the narcotic-withdrawal syndrome and sirolimus-associated pneumonitis

45 icant association between the development of withdrawal syndrome and the presence of ARDS (p = .017).

46 utcomes, pharmacologic treatment for alcohol withdrawal syndrome, and Clinical Institute Withdrawal A

47 sociated with congenital anomalies, neonatal withdrawal syndrome, and persistent pulmonary hypertensi

48 ed alcohol use leading to tolerance, alcohol withdrawal syndrome, and physical and psychological depe

49 used to treat complications such as alcohol withdrawal syndrome are often contraindicated by the pre

50 Diagnostic criteria for cannabis withdrawal syndrome are proposed.

51 olism, models for specific factors, like the withdrawal syndrome, are useful for identifying potentia

52 ntly less tolerance, and strongly attenuated withdrawal syndrome, as compared to morphine and the rec

53 Alcohol withdrawal syndrome assessment and its treatment options

54 A clinically important withdrawal syndrome associated with cannabis dependence

55 nergic agonist clonidine triggers a powerful withdrawal syndrome associated with massive CNS expressi

56 The incidence of antidepressant withdrawal syndrome (AWS) and other characteristics rema

57 IE is validated as a model for human alcohol withdrawal syndrome (AWS) by demonstrating increased lev

58 herapy is increasingly used to treat alcohol withdrawal syndrome (AWS) in hospitalized patients, but

59 Alcohol withdrawal syndrome (AWS) is a common inpatient diagnosi

60 Alcohol withdrawal syndrome (AWS) is a potentially fatal outcome

61 Alcohol withdrawal syndrome (AWS) is an important cause and comp

62 Alcohol withdrawal syndrome (AWS) occurs in 2% of patients admit

63 Alcohol withdrawal syndrome (AWS) symptoms include hyperexcitabi

64 ons into either brain region induced a quasi-withdrawal syndrome, but the observed behaviors differed

65 Although the withdrawal syndrome can be differentiated from recurrenc

66 e of GHB or its analogs is associated with a withdrawal syndrome characterized by autonomic excitatio

67 stions for an approach to the glucocorticoid withdrawal syndrome, chronic management of glucocorticoi

68 ry characteristics, risk factors for alcohol withdrawal syndrome, clinical outcomes, pharmacologic tr

69 The association between ARDS and withdrawal syndrome, combined with the observation that

70 tate tumors may confer the development of HF withdrawal syndrome, commonly diagnosed in patients with

71 gth of stay, ICU length of stay, and alcohol withdrawal syndrome complications differed significantly

72 y complex, as manifestations such as alcohol withdrawal syndrome, craving and physical dependence, as

73 verse outcomes may also result from cannabis withdrawal syndrome (CWS).

74 doses of opioids, several complications like withdrawal syndrome, delirium, mental status changes, an

75 Alcohol withdrawal syndrome developed in 0.88% (n = 246), includ

76 When nicotine is removed, a withdrawal syndrome develops.

77 he patients had signs and symptoms of opioid withdrawal syndrome during evaluation.

78 d sedative medications are at risk for acute withdrawal syndromes during drug weaning.

79 Trauma patients with alcohol withdrawal syndrome experience a high occurrence of deli

80 pecific issues included possible addition of withdrawal syndromes for several substances, alignment o

81 physical dependence, shown by an attenuated withdrawal syndrome, from cocaine and U-50,488H.

82 Benzodiazepine withdrawal syndrome has also been associated with high d

83 ity and clinical significance of a marijuana withdrawal syndrome has not been established.

84 resistance to enzalutamide and enzalutamide withdrawal syndrome have been reported.

85 o possible that individual components of the withdrawal syndrome have individual and unique rate limi

86 n of opiate therapy can cause a debilitating withdrawal syndrome in chronic users.

87 We sought to identify a clonidine withdrawal syndrome in conscious rats by investigating t

88 dictive model of risk factors for iatrogenic withdrawal syndrome in critically ill children.

89 and screening tools associated with alcohol withdrawal syndrome in the ICU are reviewed.

90 ional or alternative strategies for managing withdrawal syndromes in ICU patients should therefore be

91 ies addressing the drug treatment of alcohol withdrawal syndromes in inpatient populations, with a fo

92 acologic strategies for treatment of alcohol withdrawal syndromes in the critically ill.

93 siology, diagnosis, and treatment of alcohol withdrawal syndromes in the intensive care unit as well

94 agnosis and treatment strategies for alcohol withdrawal syndromes in the intensive care unit.

95 Infants with neonatal opioid withdrawal syndrome, in utero substance exposure, or mal

96 alyses, significant predictors of iatrogenic withdrawal syndrome included younger age, preexisting co

97 of control over intake and the presence of a withdrawal syndrome, including both motivational and phy

98 f control over intake, and the presence of a withdrawal syndrome, including both motivational and phy

99 The intensity of the withdrawal syndrome indicates that chronic exposure to a

100 H (1 microM) displayed an abstinence-induced withdrawal syndrome, indicative of the development of ph

101 Iatrogenic withdrawal syndrome is common in children recovering fro

102 2-4-week period associated with the nicotine withdrawal syndrome is indicated when abstinence is atte

103 Iatrogenic withdrawal syndrome (IWS) associated with opioid and sed

104 Opioid discontinuation generates a withdrawal syndrome marked by increased negative affect.

105 he hormone refractory stage to battle the HF withdrawal syndrome may become an alternative strategy t

106 aspirin is held preoperatively, the aspirin withdrawal syndrome may significantly increase the risk

107 by pregnant women results in neonatal opioid withdrawal syndrome (NOWS) and lifelong neurobehavioral

108 Infants with neonatal opioid withdrawal syndrome (NOWS) cared for with the Eat, Sleep

109 Although cases of neonatal opioid withdrawal syndrome (NOWS) increased 5-fold in recent ye

110 Neonatal opioid withdrawal syndrome (NOWS) is a growing public health co

111 ithdrawal in the neonate, or neonatal opioid withdrawal syndrome (NOWS), is problematic because curre

112 is commonly associated with neonatal opioid withdrawal syndrome (NOWS), which is characterized by a

113 for those not diagnosed with neonatal opioid withdrawal syndrome (NOWS).

114 ioid exposure on the risk of neonatal opioid withdrawal syndrome (NOWS).

115 birth; low birth weight; and neonatal opioid withdrawal syndrome (NOWS).

116 ugh they are associated with neonatal opioid withdrawal syndrome (NOWS).

117 pharmacologic treatment for neonatal opioid withdrawal syndrome (NOWS).

118 ified by infant diagnosis of neonatal opioid withdrawal syndrome (NOWS).

119 depression and anxiety, and neonatal opioid withdrawal syndrome (NOWS).

120 , we observed a clear impact of the Nicotine Withdrawal Syndrome (NWS) on RL, and a dynamic relations

121 due to the aversive aspects of the nicotine withdrawal syndrome (NWS), which remains poorly understo

122 Nicotine Withdrawal Syndrome (NWS)-associated cognitive deficits

123 Direct drug effects and withdrawal syndromes occurred in some neonates whose mot

124 SSRI withdrawal syndrome occurs often and can be severe, and

125 Understanding the impact of cannabis withdrawal syndrome on quit attempts is of obvious impor

126 e (10 mg/kg) to induce naloxone-precipitated withdrawal syndrome on the final day of the experiment (

127 zodiazepines, results in the production of a withdrawal syndrome, one feature of which is increased s

128 Diagnostic codes for neonatal opioid withdrawal syndrome or neonatal abstinence syndrome from

129 shown to be active in vivo, do not manifest withdrawal syndromes or reward behavior in conditioned-p

130 The role of currently published alcohol withdrawal syndrome pharmacologic strategies (benzodiaze

131 Nine (32.1%) patients developed acute withdrawal syndrome potentially related to the administr

132 bstinence syndrome (NAS) is a postnatal drug withdrawal syndrome primarily caused by maternal opiate

133 Alcohol withdrawal syndrome progressed to delirium tremens in 11

134 lcohol use disorders (AUDs) (intoxication or withdrawal syndrome), psychopathological manifestations,

135 lts with AUD, including a history of alcohol withdrawal syndrome, received 1,200 mg/day of gabapentin

136 ratory and clinical studies indicates that a withdrawal syndrome reliably follows discontinuation of

137 alternative symptom severity scales, severe withdrawal syndromes resistant to benzodiazepine drugs,

138 eline CIWA-Ar score, and established alcohol withdrawal syndrome risk factors.

139 Background: Severe alcohol withdrawal syndrome (SAWS) is highly morbid, costly, and

140 In patients with severe alcohol withdrawal syndrome, severe head injury also predicted p

141 plications differed significantly by alcohol withdrawal syndrome severity and were worse with more se

142 ality also significantly differed by alcohol withdrawal syndrome severity but was only greater in pat

143 Before adjustment, alcohol withdrawal syndrome severity was associated with injury

144 Alcohol withdrawal syndrome severity was defined by CIWA-Ar scor

145 who are cannabis users may develop cannabis withdrawal syndrome shortly after hospital admission, an

146 overdosed in the intensive care unit, though withdrawal syndromes should be prevented, and communicat

147 tically ill patients including pain, alcohol withdrawal syndrome, status epilepticus, and acute agita

148 pain, sedation, status asthmaticus, alcohol withdrawal syndrome, status epilepticus, and acute behav

149 eously providing relief from the craving and withdrawal syndrome that accompanies cessation attempts.

150 ated prostate tumor growth, the antiandrogen withdrawal syndrome that allows antiandrogens to stimula

151 in chronic opiate abusers produces a severe withdrawal syndrome that is highly aversive, and avoidan

152 of the neonatal abstinence syndrome, a drug-withdrawal syndrome that most commonly occurs after in u

153 non-y-aminobutyric acid pathways for alcohol withdrawal syndrome treatment; 2) harnessing retrospecti

154 eported by patients given pregabalin, and no withdrawal syndrome was associated with pregabalin treat

155 Iatrogenic withdrawal syndrome was defined as having at least two W

156 The presence or absence of acute withdrawal syndrome was identified for each patient.

157 Nicotine withdrawal syndrome was precipitated by mecamylamine (2

158 ne receptor is relevant for the onset of the withdrawal syndrome, we used a mouse model of nicotine w

159 r of days until infants with neonatal opioid withdrawal syndrome were medically ready for discharge,

160 syndrome, combined with the observation that withdrawal syndromes were also associated with the use o

161 uscular blockers, pain assessments, and drug withdrawal syndromes were gathered during the first 28 d

162 s syndrome and, subsequently, glucocorticoid withdrawal syndrome when the treatment is tapered down.

163 ls, we enrolled infants with neonatal opioid withdrawal syndrome who had been born at 36 weeks' gesta